Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Moodys
Merck
Johnson and Johnson
Express Scripts

Last Updated: May 21, 2022

CLINICAL TRIALS PROFILE FOR VASOPRESSIN


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Vasopressin

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed Northwestern University 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004360 ↗ Study of Genotype and Phenotype Expression in Congenital Nephrogenic Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-09-01 OBJECTIVES: I. Determine the relationship between genotype variations and clinical phenotype in patients with congenital nephrogenic diabetes insipidus.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed Northwestern University 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004363 ↗ Study of the Pathogenesis and Pathophysiology of Familial Neurohypophyseal Diabetes Insipidus Completed National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Determine whether diverse mutations of the vasopressin-neurophysin II (AVP-NPII) gene cause autosomal dominant familial neurohypophyseal diabetes insipidus by directing the production of an abnormal preprohormone. II. Determine whether the AVP-NPII gene-directed preprohormone accumulates and destroys magnocellular neurons because it cannot be folded and processed efficiently.
NCT00004364 ↗ Study of Novel Types of Familial Diabetes Insipidus Unknown status Northwestern University 1995-12-01 OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
NCT00004364 ↗ Study of Novel Types of Familial Diabetes Insipidus Unknown status National Center for Research Resources (NCRR) 1995-12-01 OBJECTIVES: I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
NCT00032734 ↗ Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion Completed Sanofi Phase 2 2001-06-01 The study is designed to assess the efficacy of an investigational drug called SR121463B (vasopressin receptor antagonist) in the treatment of low levels of sodium in the blood associated with the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH). This double blind period study is followed by 2 open label extension studies with flexible doses of satavaptan.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Vasopressin

Condition Name

Condition Name for Vasopressin
Intervention Trials
Septic Shock 23
Hyponatremia 13
Healthy 11
Cardiac Arrest 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Vasopressin
Intervention Trials
Shock 35
Shock, Septic 27
Heart Failure 19
Hyponatremia 15
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Vasopressin

Trials by Country

Trials by Country for Vasopressin
Location Trials
United States 318
Canada 27
Germany 20
Italy 17
Greece 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Vasopressin
Location Trials
California 21
New York 19
Texas 17
Ohio 16
Illinois 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Vasopressin

Clinical Trial Phase

Clinical Trial Phase for Vasopressin
Clinical Trial Phase Trials
Phase 4 46
Phase 3 33
Phase 2/Phase 3 17
[disabled in preview] 124
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Vasopressin
Clinical Trial Phase Trials
Completed 133
Recruiting 28
Unknown status 27
[disabled in preview] 40
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Vasopressin

Sponsor Name

Sponsor Name for Vasopressin
Sponsor Trials
Vantia Ltd 8
Multidisciplinary Association for Psychedelic Studies 7
National Institute of Mental Health (NIMH) 7
[disabled in preview] 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Vasopressin
Sponsor Trials
Other 294
Industry 67
NIH 16
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Medtronic
Colorcon
McKesson
Johnson and Johnson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.